Cargando…

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics

Deeper understanding of the pathobiology of non-small-cell lung cancer (NSCLC) has led to the development of small molecules that target genetic mutations known to play critical roles in the progression to metastatic disease. The discovery of epidermal growth factor receptor (EGFR) mutations in 15%–...

Descripción completa

Detalles Bibliográficos
Autores principales: Karachaliou, Niki, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217512/
https://www.ncbi.nlm.nih.gov/pubmed/28210145
http://dx.doi.org/10.2147/LCTT.S50671